BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development. The Company plans to seek guidance in Q3 2025 ...

Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin ...

WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the ...

Fractyl has built its patent portfolio since 2011, and its IP estate now includes 31 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and ...

Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership ...

Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise. Company Also Hires ...